Correlation of B-cell-activating Factor Levels and Diseases Activity in Systemic Lupus Erythematosus Patients

被引:1
|
作者
Vitri, Ria Yolanda [1 ]
Wachjudi, Rachmat Gunadi [2 ]
Ghassani, Nadia Gita [3 ]
Hamijoyo, Laniyati [2 ,3 ]
机构
[1] Univ Padjadiaran, Fac Med, Dept Internal Med, Hasan Sadikin Gen Hosp, Bandung, Indonesia
[2] Univ Padjadiaran, Fac Med, Dept Internal Med, Hasan Sadikin Gen Hosp,Div Rheumatol, Bandung, Indonesia
[3] Univ Padjadjaran, Fac Med, Immunol Study Ctr, Lupus Study Grp, Jalan Prof Eyckman 38, Bandung 40161, West Java, Indonesia
关键词
B-cell-activating factor; disease activity; Indonesia; systemic lupus erythematosus; Systemic Lupus Erythematosus Disease Activity Index 2000; BAFF; CLASSIFICATION; CRITERIA; BLYS;
D O I
10.4103/injr.injr_122_20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: B-cell hyperactivity is believed to have a central role in the pathogenesis of systemic lupus erythematosus (SLE). B-cell-activating factor (BAFF) is a cytokine that plays a role in accelerating maturation, differentiation, and survival of B-cells. The purpose of this study is to determine whether there is a significant association between the serum BAFF levels and disease activity in SLE patients. Subjects and Methods: This study uses bivariate analysis with a cross-sectional design. The statistical analysis test used is Pearson's and Spearman's correlation coefficient test, as well as Mann-Whitney test. Participants were 44 SLE patients with active disease (SLEDAI 2K >2) in the rheumatology clinic and in-patient wards of Hasan Sadikin General Hospital, Department of Internal Medicine, Bandung, during the period of December 2016-March 2017. Results: Forty-four participants of the study were women with a mean age of 28 +/- 8 years. Renal (93.2%) and mucocutaneous (93.2%) involvements were the most common manifestations. Median of disease activity based on SLEDAI-2K score was 8 (4-23). Median serum BAFF level was 1.218 ng/ml (0.476-10.835). There was a weak positive correlation between serum BAFF levels and SLEDAI-2K (r = 0.327, P = 0.015). There was also a significant correlation with weak relation found between serum BAFF levels and anti-dsDNA and complement C3 levels. Conclusion: There is a significant correlation between the serum levels of BAFF and SLE disease activity. However, the strength of the relationship is weak. Therefore, disease activity in lupus can be influenced by other factors.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 50 条
  • [1] Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus
    Vincent, F. B.
    Kandane-Rathnayake, R.
    Hoi, A. Y.
    Slavin, L.
    Godsell, J. D.
    Kitching, A. R.
    Harris, J.
    Nelson, C. L.
    Jenkins, A. J.
    Chrysostomou, A.
    Hibbs, M. L.
    Kerr, P. G.
    Rischmueller, M.
    Mackay, F.
    Morand, E. F.
    [J]. LUPUS, 2018, 27 (13) : 2029 - 2040
  • [2] Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity
    Rezazadeh, Maryam
    Jokar, Mohammad Hasan
    Aghili, Seyedeh Mehrnaz
    Mirfeizi, Zahra
    Mahmoudi, Mahmoud
    Morovatdar, Negar
    Hashemzadeh, Kamila
    [J]. ARCHIVES OF RHEUMATOLOGY, 2023, 38 (03) : 429 - 440
  • [3] B- Cell Activating Factor Promoter Polymorphisms in Egyptian Patients with Systemic Lupus Erythematosus
    Zayed, Rania A.
    Sheba, Hala F.
    Elazaem, Mennat Allah K. Abo
    Elsaadany, Zainab A.
    Elmessery, Lobna O.
    Mahmoud, Jelan A.
    Rahman, Dalia R. Abdel
    Abdou, Faten R.
    [J]. ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2013, 43 (03): : 289 - 294
  • [4] Longitudinal study of B-lymphocyte activating factor levels in systemic lupus erythematosus
    Becker-Merok, A.
    Nossent, H. C.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 39 - 39
  • [5] EFFECTS OF BLISIBIMOD, AN INHIBITOR OF B CELL ACTIVATING FACTOR, ON PATIENT REPORTED OUTCOMES AND DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Petri, M.
    Martin, R. S.
    Hislop, C.
    Scheinberg, M. A.
    Furie, R. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 336 - 337
  • [6] B cell activating factor in juvenile onset systemic lupus erythematosus, looking beyond the B cell
    Ella Richards
    Angela Midgely
    Thomas Morgan
    Michael Beresford
    [J]. Pediatric Rheumatology, 12 (Suppl 1)
  • [7] Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)
    Stohl, William
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (06) : 623 - 633
  • [8] High B-cell-activating factor levels in endemic Tunisian pemphigus
    Mejri, Kaouthar
    Sellami, Maryam Kallel
    Zaraa, Ines Rania
    Laadhar, Lilia
    Lahmar, Houria
    Mokni, Mourad
    Mokhtar, Insaf
    Fezza, Bacima
    Zitouni, Mondher
    Makni, Sondes
    [J]. INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2017, 83 (04): : 496 - +
  • [9] No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus
    Buskila, D
    Lorber, M
    Neumann, L
    Flusser, D
    Shoenfeld, Y
    [J]. JOURNAL OF RHEUMATOLOGY, 1996, 23 (04) : 629 - 632
  • [10] B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis
    Theodorou, Evangelos
    Nezos, Adrianos
    Kostantopoulou, Pinelopi
    Tektonidou, Maria
    Koutsilieris, Michael
    Mavragani, Clio P.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68